中信证券股份有限公司关于 华润博雅生物制药集团股份有限公司 向特定对象发行股票并在创业板上市 之持续督导保荐总结报告书 | | | 一、发行人基本情况 | 项目 | 内容 | | --- | --- | | 发行人名称 | 华润博雅生物制药集团股份有限公司 | | 证券代码 | 300294.SZ | | 注册资本 | 504,248,738元 | | 注册地址 | 江西省抚州市高新技术产业园区惠泉路333号 | | 主要办公地址 | 江西省抚州市高新技术产业园区惠泉路333号 | | 法定代表人 | 梁小明 | | 董事会秘书 | 梁化成 | | 联系电话 | 0794-8264398 | | 本次证券发行类型 | 向特定对象发行股票 | | 本次证券上市时间 | 2021年11月25日 | | 本次证券上市地点 | 深圳证券交易所 | 二、本次发行情况概述 经中国证监会《关于同意博雅生物制药集团股份有限公司向特定对象发行股 票注册的批复》（证监许可﹝2021﹞3340 号）核准，博雅生物制药集团股份有限 公司（以下简称"公司"）以 31.37 元/股向特定对象华润医药控股有限公司发行股 份 78,308, ...

中信证券股份有限公司 关于华润博雅生物制药集团股份有限公司 2023 年年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：博雅生物 | | --- | --- | | 保荐代表人姓名：赵洞天 | 联系电话：010-60838275 | | 保荐代表人姓名：黄江宁 | 联系电话：010-60836569 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次 | 次 0 | | 数 | | | 2．督导公司建立健全并有效执行规章制 | | | 度的情况 | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的 | 是 | | 制度、募集资金管理制度、内控制度、内 | | | 部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是，根据 2023 年度内控自我评价报告、 | | | 2023 年度内部控制审计报告，发行人 | | | 有效执行了相关规章制度 | | 3.募集资金监督 ...

中信证券股份有限公司 关于华润博雅生物制药集团股份有限公司 2023 年度持续督导定期现场检查报告 | 保荐人名称：中信证券股份有限公司 被保荐公司简称：博雅生物 | | --- | | （以下简称"中信证券"或"保荐人"） | | 保荐代表人姓名：赵洞天 联系电话：010-60838275 | | 保荐代表人姓名：黄江宁 联系电话：010-60836569 | | 现场检查人员姓名：赵洞天、朱印 | | 现场检查对应期间：2023 年 1 月 1 日-2023 年 12 月 31 日 | | 年 月 日至 年 月 日 现场检查时间：2024 3 19 2024 3 28 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段： | | 查阅了上市公司最新章程、三会议事规则及会议材料，取得上市公司董事、监事、 | | 高级管理人员名单及其变化情况，取得上市公司关联方清单，查阅关于公司控股 | | 股东、实际控制人、董事、监事、高级管理人员的信息披露文件及相关变更决策 | | 文件，查看上市公司生产经营场所，对上市公司董事、高级管理人员进行访谈。 | | 3.三会会 ...

Board and Management Changes - The company held the 29th meeting of the 7th Board of Directors on March 4, 2024, approving the election of candidates for the 8th Board of Directors, including Mr. Qiu Kai and Mr. Liang Xiaoming as non-independent directors[1]. - The term of the independent directors Mr. Zhang Weidong, Mr. Zhao Li, and Mr. Huang Huasheng will end on February 2, 2027[2]. - The company elected Mr. Rao Zhen as the employee representative supervisor during the 6th meeting of the 6th Employee Representative Assembly on March 11, 2024[1]. - The 8th Board of Directors held its first meeting on March 21, 2024, where it approved the election of the chairman and the appointment of senior management personnel[1]. - The company has experienced changes in its board and management personnel, with several new appointments effective from October 25, 2023[5]. - The new board members include Mr. Qiu Kai as Chairman and Mr. Liang Xiaoming as President, both with extensive backgrounds in the pharmaceutical industry[6]. - The company is expanding its governance structure with the election of independent directors and supervisors to enhance oversight and compliance[2]. - The company’s leadership changes are aimed at driving future growth and innovation in the pharmaceutical sector[6]. Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.2 billion for the fiscal year 2023, representing a year-on-year growth of 15%[146]. - The company's operating revenue for 2023 was ¥2,651,979,506.66, a decrease of 3.87% compared to ¥2,758,701,315.10 in 2022[154]. - The net profit attributable to shareholders for 2023 was ¥237,465,593.87, down 45.06% from ¥432,197,553.97 in 2022[154]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥143,075,746.77, a decline of 63.51% compared to ¥392,124,538.69 in 2022[154]. - The gross margin for the year was reported at 45%, a slight decrease from 48% in the previous year, attributed to increased raw material costs[146]. - The company reported a loss of CNY 3,894.56 million from the transfer of 89.681% equity of Guizhou Tianan Pharmaceutical Co., Ltd.[126]. - The company reported a net profit loss in the fourth quarter primarily due to a goodwill impairment provision of CNY 298.41 million related to the acquisition of Nanjing Xinbai Pharmaceutical Co., Ltd.[186]. Compliance and Governance - The company is committed to maintaining compliance with the regulations regarding independent directors, ensuring governance best practices[2]. - The company has received regulatory measures from the China Securities Regulatory Commission for information disclosure violations, which have been recorded in the integrity archives[15]. - The company is committed to ensuring the legality of economic contracts and major investment decisions, with a 100% legal review of important regulations and contracts[30]. - The internal control system has been strengthened, with timely reviews and updates to internal control procedures across various business areas, ensuring effective implementation[29]. - The company has reported no significant internal control deficiencies during the reporting period, indicating a robust internal control environment[33]. - The company has no violations or rectification situations during the reporting period[117]. - The company maintains a good integrity status for itself and its controlling shareholders[118]. Marketing and Strategic Focus - The company aims to enhance plasma station management capabilities, focusing on cost control and establishing benchmark stations to promote internal growth[20]. - The company plans to implement marketing reforms by adopting a refined招商 business model and building its own sales team to improve channel control and brand influence[22]. - The company is focused on increasing plasma collection volume by enhancing brand marketing and emotional engagement with donors[20]. - The company has a strategic focus on leveraging cornerstone products to drive sales and improve marketing effectiveness through targeted strategies[22]. - The company is accelerating marketing transformation and restructuring its marketing model to enhance management capabilities and focus on terminal hospital development and pure sales management[23]. - The company aims to increase market share by implementing targeted marketing strategies for core products such as pituitary posterior lobe, oxytocin, and bone peptide tablets, with a focus on developing blank areas[23]. Research and Development - The company is enhancing its innovative R&D capabilities by introducing or developing new products and activating the commercial value of dormant varieties to accelerate project sales[25]. - The company acknowledges that the development and launch of new blood products involve a lengthy and high-risk process, requiring significant resources and funding[24]. - Research and development expenses increased by 25% to RMB 150 million, reflecting the company's commitment to innovation[146]. - The company has established strategic partnerships with two leading research institutions to accelerate the development of new therapies[146]. - The company is actively developing new products, including a novel immunoglobulin therapy expected to enter clinical trials in Q2 2024[146]. Environmental Compliance - Huaren Boya Bio's existing projects have passed environmental impact assessments and obtained valid discharge permits[41]. - The company reported a COD level of 81.220 mg/L, which is below the national standard of 220 mg/L, with a total discharge of 4.885 tons[46]. - New Bai Pharmaceutical's gas emissions for non-methane total hydrocarbons were recorded at 0.49 mg/m³, significantly below the standard of 4 mg/m³[46]. - The company has received environmental impact report approvals for multiple construction projects, ensuring compliance with environmental regulations[41]. - The company has implemented pollution prevention measures in accordance with the environmental impact reports for its construction projects[40]. - The company has established a comprehensive pollution prevention and control system, ensuring compliance with environmental regulations[58]. - The company has implemented an automatic monitoring system for VOCs, which will enable real-time monitoring of volatile organic compounds after installation[63]. Social Responsibility - The company has invested a total of 2.62 million yuan in poverty alleviation efforts, focusing on improving educational resources in impoverished areas[82]. - The company allocated 150,000 yuan towards healthcare resources in impoverished regions as part of its poverty alleviation initiatives[85]. - The company has implemented a comprehensive employment strategy that promotes equal opportunities and adheres to labor laws, ensuring fair treatment of all employees[73]. Related Party Transactions - The total amount of related party transactions with China Resources Pharmaceutical Holdings and its affiliates reached CNY 29,636.92 million, accounting for 9.91% of similar transactions[121]. - The company sold 75% equity of Guangdong Fuda Pharmaceutical Co., Ltd. for CNY 36,476.42 million, resulting in a profit of CNY 3,427.62 million[123]. - The company has approved a transaction limit of CNY 31,320.00 million for related party transactions, which was not exceeded[121]. - The company reported a significant increase in user data, with a year-over-year growth of 29.34% in purchasing goods from related parties[121]. - The company has no significant related party transactions or loans during the reporting period[158][159]. Market Outlook - Looking ahead, the company projects a revenue growth of 10% for 2024, targeting RMB 1.32 billion in total revenue[146]. - The blood products industry is expected to maintain a stable growth trend due to the increasing demand for products like immunoglobulin and the stable pricing system established in the Beijing-Tianjin-Hebei region[200]. - By 2027, the Chinese blood products market is expected to reach CNY 78 billion, with a compound annual growth rate (CAGR) of 11.6% from 2022 to 2027[196]. - The number of newly operational plasma stations in China in 2023 was 33, indicating an acceleration in industry consolidation[196].

证券代码：300294 证券简称：博雅生物 公告编号：2023-057 华润博雅生物制药集团股份有限公司 关于单采血浆站取得《营业执照》的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，华润博雅生物制药集团股份有限公司（以下简称公司）下属单采血浆 站"泰和博雅单采血浆有限公司"（以下简称泰和浆站）和"乐平市博雅单采血 浆有限公司"（以下简称乐平浆站）取得市场监督管理局颁发的《营业执照》， 其相关信息如下： 泰和浆站、乐平浆站均为公司全资子公司，上述浆站将按照相关法律法规及 标准要求进行建设，建成后根据《单采血浆站管理办法》等有关要求提交执业申 请，经验收合格后开展采浆工作。 公司将根据上述单采血浆站建设的进展情况及时进行信息披露。 特此公告。 华润博雅生物制药集团股份有限公司董事会 2023 年 11 月 20 日 一、泰和博雅单采血浆有限公司《营业执照》信息 二、乐平市博雅单采血浆有限公司《营业执照》信息 名 称：泰和博雅单采血浆有限公司 统一社会信用代码：91360826MAD598XD2P 类 型：有限责任公司(非自然人投资或控股的法人独资) 住 ...

华润博雅生物制药集团股份有限公司（以下简称公司）全资子公司南京新百 药业有限公司（以下简称新百药业）和江西博雅欣和制药有限公司（以下简称欣 和制药）于 2023 年 11 月 6 日参加了国家组织药品联合采购办公室（以下简称联 采办）组织的第九批全国药品集中采购的投标工作。新百药业的缩宫素注射液和 欣和制药的西他沙星片拟中选本次集中采购，现将相关情况公告如下： 证券代码：300294 证券简称：博雅生物 公告编号：2023-056 注：1、上述品种的具体中选情况以联采办发布的最终数据为准。 华润博雅生物制药集团股份有限公司 2、本次拟中选产品的采购周期自中选结果执行之日起至 2027 年 12 月 31 日。 关于子公司拟中选第九批全国药品集中采购的公告 3、按照相关规定，采购周期内采购协议每年一签。续签采购协议时，约定采购量原则上不少于各 地该中选药品上年约定采购量。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 二、本次拟中选对公司的影响 2023 年 11 月 8 日 三、风险提示 新百药业和欣和制药已与联采办签订了相关的《全国药品集中采购拟中选品 种主供地 ...

公司于 2023 年 11 月 2 日接到天安药业转贵州省市场监督管理局的《登记通 知书》，天安药业完成了上述股权转让的相关工商变更登记手续。上述股权转让 后，公司不再持有天安药业的股权。 特此公告。 华润博雅生物制药集团股份有限公司董事会 证券代码：300294 证券简称：博雅生物 公告编号：2023-055 华润博雅生物制药集团股份有限公司 关于转让贵州天安药业股份有限公司 89.681%股权事项进展的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）于 2023 年 9 月 26 日召开第七届董事会第二十四次会议、第七届监事会第二十一次会议，审议通过 《关于转让贵州天安药业股份有限公司 89.681%股权暨关联交易的议案》，公司 以 260,355,691.22 元将贵州天安药业股份有限公司（以下简称天安药业）89.681% 股权转让给华润双鹤药业股份有限公司。具体内容详见公司 2023 年 9 月 28 日在 巨潮资讯网披露的《关于转让贵州天安药业股份有限公司 89.681%股权暨关联交 易的公告》（公告编 ...

Financial Performance - The company's operating revenue for the current period is ¥649,526,615.39, a decrease of 5.04% compared to the same period last year[1] - The net profit attributable to shareholders for the current period is ¥138,149,317.69, down 0.93% year-on-year[1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is ¥103,864,621.69, a decrease of 4.20% compared to the same period last year[1] - Total operating revenue for the third quarter was CNY 2,190,398,869.51, an increase of 5.3% compared to CNY 2,082,744,315.52 in the previous year[41] - Net profit attributable to shareholders of the parent company reached CNY 464,067,798.65, representing a 10.9% increase from CNY 418,279,088.07 in the prior year[46] - The net profit for the third quarter was 474,089,330.24, an increase of 10.6% compared to 428,899,020.70 in the previous year[54] - Operating profit increased to 577,182,286.70, reflecting a growth of 14.2% from 505,255,213.36 year-over-year[54] Assets and Liabilities - The total assets at the end of the current period amount to ¥8,182,958,918.52, reflecting a 1.86% increase from the end of the previous year[1] - Total assets increased to CNY 8,182,958,918.52, compared to CNY 8,033,175,408.45 at the end of the previous period[41] - Total liabilities decreased to CNY 610,247,338.68 from CNY 748,348,858.19 in the previous year[41] - Non-current liabilities totaled CNY 53,977,140.53, an increase from CNY 43,011,597.58 in the previous year[41] - The company’s total equity increased to CNY 7,572,711,579.84 from CNY 7,284,826,550.26 in the previous year[41] Cash Flow - Cash flow from operating activities netted 525,706,132.68, compared to 377,007,297.33 in the previous year, marking a 39.4% increase[55] - Cash inflow from investment activities totaled 3,992,659,220.89, up from 3,448,467,134.16, indicating a growth of 15.8%[55] - The cash flow from investment activities showed a net outflow of -519,774,432.72, an improvement from -778,543,985.54 in the previous year[57] Research and Development - Research and development expenses for the first nine months of 2023 are ¥48,042,073.01, an increase of 34.85% compared to the same period last year[7] - Research and development expenses rose to 48,042,073.01, up 34.7% from 35,626,723.74 in the same period last year[54] - The company’s development expenses increased by 43.85% to CNY 54,494,597.21 due to increased R&D investments[29] Equity Transactions - The company transferred 75% equity of Guangdong Fuda Pharmaceutical Co., Ltd. for ¥364,764,150 to China Resources Pharmaceutical Group Co., Ltd.[15] - The company transferred 75% equity of Guangdong Fuda Pharmaceutical Co., Ltd. and no longer holds any shares in it[26] - The company sold 89.681% equity of Guizhou Tianan Pharmaceutical Co., Ltd. for CNY 260.36 million to China Resources Double Crane Pharmaceutical Co., Ltd.[28] Other Income and Expenses - The company reported a significant increase in other income, which rose by 240.53% to ¥18,829,417.54 due to increased government subsidies[7] - The fair value change income increased by 251.95% to ¥75,712,202.18, attributed to gains from financial products[7] - The company reported a total tax expense of 101,112,893.62, which is an increase from 75,129,153.47, reflecting a rise of 34.6%[54] Shareholder Information - The company’s total number of common stock shareholders at the end of the reporting period was 22,290[24] - The largest shareholder, China Resources Pharmaceutical Group Co., Ltd., holds 29.28% of the shares[24] Inventory and Receivables - Accounts receivable decreased by 44.11% to CNY 258,064,802.50 due to the divestment of Fuda Pharmaceutical and improved cash collection[29] - Other receivables increased by 252.08% to CNY 354,264,211.27 primarily due to the receivable from the transfer of Fuda Pharmaceutical equity[29] - The company’s inventory decreased to CNY 579,701,942.68 from CNY 666,962,605.02 in the previous year[41] Future Plans - The company plans to establish single plasma collection stations in Taihe County and Le Ping City, pending regulatory approvals[37] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[54]

华润博雅生物制药集团股份有限公司 关于选举董事长及补选董事会各专门委员会委员的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：300294 证券简称：博雅生物 公告编号：2023-052 特此公告。 华润博雅生物制药集团股份有限公司董事会 2023 年 10 月 25 日 华润博雅生物制药集团股份有限公司（以下简称公司）于 2023 年 10 月 25 日召开第七届董事会第二十六次会议，审议通过《关于选举董事长的议案》《关 于补选第七届董事会各专门委员会委员的议案》，会议同意选举邱凯先生为公司 第七届董事会董事长、第七届董事会战略委员会委员（召集人）、第七届董事会 提名、薪酬与考核委员会委员；同意选举申劲锋先生为公司第七届董事会战略委 员会委员。上述人员任期自本次董事会审议通过之日起至第七届董事会届满之日 止。 ...

证券代码：300294 证券简称：博雅生物 公告编号：2023-053 华润博雅生物制药集团股份有限公司 第七届董事会第二十六次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：9 票同意、0 票反对、0 票弃权 1.2 关于补选第七届董事会提名、薪酬与考核委员会委员的议案 表决结果：9 票同意、0 票反对、0 票弃权 详见中国证监会指定的创业板信息披露网站巨潮资讯网的《关于选举董事长 华润博雅生物制药集团股份有限公司（以下简称公司）第七届董事会第二十 六次会议于 2023 年 10 月 20 日以邮件及通讯方式通知，并于 2023 年 10 月 25 日以现场加通讯表决的方式召开。会议应到董事 9 人，实到董事 9 人。经半数以 上董事推举，会议由董事邱凯先生主持。公司监事及高级管理人员列席了会议。 本次会议符合《中华人民共和国公司法》（以下简称《公司法》）《中华人民共 和国证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关规 定 ...